David W. OSBORNE,Bhaskar CLAUDHURI,Archie W. THURSTON, Jr.
申请号：
US16778845
公开号：
US20200163944A1
申请日:
2020.01.31
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.
